bluuebunny/crossref_metadata_2025_split huggingface dataset:
Hyperperfusion of Cerebral Cortex, Thalamus and Basal Ganglia During Spontaneously Occurring Migraine Headaches
Authors: Kobari Masahiro , Meyer John Stirling , Ichijo Makoto , Imai Akira , Oravez William T. 
Published: June 2005

SYNOPSISColor‐coded, cross‐sectional imaging of local cerebral blood flow (LCBF) was made in a prospective manner among 22 patients with well‐established common or classic migraine utilizing the stable xenon‐enhanced computed tomographic (Xe CT‐CBF) method. LCBF in patients during spontaneously occurring headaches (N = 12) were significantly higher compared to patients without headache (N = 10) by 25–35%. The hyperperfusion involved not only cerebral cortex but also sub‐cortical structures including thalamus, basal ganglia, and sub‐cortical white matter. LCBF increases were bilateral and sometimes asymmetrical, but LCBF increases were not consistently related to the preponderant side of headache. No significant differences were observed in the degree or pattern of cerebral hyperperfusion during headaches compared among common (N = 6) and classic (N = 6) migraineurs.Results suggest a common etiology for both common and classic migraine. Results are not consistent with spreading oligemia or spreading cortical depression as a cause of migraine. The cerebral hyperperfusion appears to be mediated by various neurogenic and chemical changes accompanying migraine. The unilateral nature of migraine head pain is more likely due to dilation of extracranial vessels.
The Role of Psychopathology in Chronic Headache: Cause or Effect?
Authors: Blanchard Edward B. , Kirsch Cynthia A. , Appelbaum Kenneth A. , Jaccard James 
Published: June 2005

SYNOPSISThe psychological test results (BDI, STAI, PSC, and MMPI Scales 1, 2, 3, and 7) of 492 chronic headache patients were subjected to five analyses in order to test two hypotheses about the relation of headache activity and psychopathology/ personality: (H‐1), that psychopathology “causes” headache; and (H‐2), that headache “causes” psychopathology. No support was found for H‐2. There was modest support for H‐1.
Brain Imaging with 123I‐IMP‐SPECT in Migraine Between Attacks
Authors: Schlake H.‐P. , Böttger I.G. , Grotemeyer K.‐H. , Husstedt I.W. 
Published: June 2005

SYNOPSIS 123I‐IMP‐SPECT brain imaging was performed in patients with classic migraine (n=5) and migraine accompagnée (n =18) during the headache‐free interval. A regional reduction of tracer uptake into brain was observed in all patients with migraine accompagnée, while in patients with classic migraine only one case showed an area of decreased activity. The most marked alteration was found in a patient with persisting neurological symptoms (“complicated migraine”). In most cases the areas of decreased tracer uptake corresponded to headache localization as well as to topography of neurologic symptoms during migraine attacks. It may be concluded that migraine attacks occur in connection with exacerbations of preexisting changes of cerebral autoregulation due to endogenous or exogenous factors.
Menstrual Migraine and Intermittent Ergonovine Therapy
Authors: Gallagher R. Michael 
Published: June 2005

SYNOPSISThe treatment of patients suffering with menstrual migraine is sometimes a difficult and frustrating problem for the physician. As many menstrual migraine headaches are refractory to abortive therapy, prophylactic therapy is often needed. Ergonovine maleate, an ergot derivative with vasoconstrictive properties, has been used with some success in migraine headache patients. Forty patients who were treated with intermittent prophylactic ergonovine were studied over six months. The patients ranged in age from 22 to 40 years, and all suffered with menstrual migraine headaches which were refractory to abortive therapy. Each patient took ergonovine maleate 0.2 mg three to four times daily during menses and recorded headache occurrence and severity. After three months, 24 patients (60%) reported significantly less severe attacks, six patients (15%) reported less frequent headaches and 14 patients (35%) reported no improvement. After six months there was a decrease in effectiveness with 20 patients (50%) reporting significantly less severe headaches and two patients (5%) reporting less frequent headaches. This limited study suggests that ergonovine maleate may be of value in the treatment of difficult menstrual migraine patients.
Regional Cerebral Blood Flow in Childhood Headache
Authors: Roach E.S. , Stump David A. 
Published: June 2005

SYNOPSISRegional cerebral blood flow (rCBF) was measured in 16 cranial regions in 23 children and adolescents with frequent headaches using the non‐invasive Xenon‐133 inhalation technique. Blood flow response to 5% carbon dioxide (CO2) was also determined in 21 patients, while response to 50% oxygen was measured in the two patients with hemoglobinopathy. Included were 10 patients with a clinical diagnosis of migraine, 4 with musculoskeletal headaches, and 3 with features of both types. Also studied were 2 patients with primary thrombocythemia, 2 patients with hemoglobinopathy and headaches, 1 patient with polycythemia, and 1 with headaches following trauma. With two exceptions, rCBF determinations were done during an asymptomatic period. Baseline rCBF values tended to be higher in these young patients than in young adults done in our laboratory. Localized reduction in the expected blood flow surge after CO2 inhalation, most often noted posteriorly, was seen in 8 of the 13 vascular headaches, but in none of the musculoskeletal headache group. Both patients with primary thrombocythemia had normal baseline flow values and altered responsiveness to CO2 similar to that seen in migraineurs; thus, the frequently reported headache and transient neurologic signs with primary thrombocythemia are probably not due to microvascular obstruction as previously suggested. These data support the concept of pediatric migraine as a disorder of vasomotor function and also add to our knowledge of normal rCBF values in younger patients. Demonstration of altered vasomotor reactivity to CO2 could prove helpful in children whoseheadache is atypical.
Acute Demyelination Mimicking Vascular Hemicrania
Authors: Nager Benjamin J. , Lanska Douglas J. , Daroff Robert B. 
Published: June 2005

SYNOPSISA 29‐year‐old woman presented with acute hemicrania, trigeminal neuropathy and posterior fossa dysfunction. The admission differential diagnosis included vertebral artery dissection, posterior circulation aneurysm, vascular malformation and brainstem infarction. However, radiographic and CSF studies indicated demyelination. Acute demyelination should be in the differential diagnosis of vascular hemicrania with signs of posterior fossadysfunction.
Pituitary Adenoma Presenting as Painful Intermittent Third Nerve Palsy
Authors: Cano M. , Lainez J.M. , Escudero J. , Barcia C. 
Published: June 2005

SYNOPSISWe report the case of a woman with short nocturnal attacks of peri‐ and retro‐orbital pain, diplopia, ptosis, rhinorrhea and lacrimation of five months evolution. Neurological examination was normal between attacks. The latter presented with partial third nerve palsy, which finally became complete and permanent. Brain CT showed a sellar and supraseller tumor with parasellar extension to the right side. We stress the atypical clinical presentation and evolution of this case, and discuss its pathophysiology.
Longterm Prognosis of Analgesic Withdrawal in Patients with Drug‐Induced Headaches
Authors: Baumgartner Christoph , Wessely Peter , Bingöl Cicek , Maly Joachim , Holzner Felix 
Published: June 2005

SYNOPSISWe studied long‐term prognosis and prognostic variables for therapeutic outcome of analgesic withdrawal in 54 patients with drug‐induced headaches. The duration of headache history was 21.9 ± 12.8 years. Each patient took an average of 38.8±22.8 tablets or suppositories a week and an average of 2.5 distinct drugs. Most patients used drugs containing several components. Caffeine was contained in at least one drug in all cases, ergotamine in 80.0% and pyrazolon in 77.1%. All patients were admitted to the hospital for two weeks. The analgesics were discontinued abruptly and the withdrawal symptoms were alleviated by neuroleptics and neurotropics. During the second week of hospital stay we started a basic therapy with calcium antagonists or beta blockers in patients suffering from migraine initially and with tricyclic antidepressants, physical therapy or biofeedback in patients suffering from tension type headaches initially. At the end of the study (mean follow‐up period = 16.8±13.6 months) 38 patients (70.1%) were evaluated. 76.3% of these patients had significantly reduced their analgesic intake, 60.5% had experienced a significant relief of headache both in intensity and frequency, and 23.7% were therapeutic failures. Analysis of the time course of relapse revealed the first six month after hospital discharge as the critical period determining long‐term success. The variables tested for prognostic relevance (age, sex,duration of headache history, number of tablets or suppositories taken a week, organic mental syndrome, and type of initial headaches) were not statistically significant.
Failure of Mexiletine to Control Trigeminal Neuralgia
Authors: Pascual Julio , Berciano José 
Published: June 2005

SYNOPSISThe analgesic effects of lidocaine and tocainide on trigeminal neuralgia have been established. However, both drugs are unpractical: lidocaine can only be used intravenously, and tocainide may exhibit serious haematological side effects. Mexiletine, a structural analogue of lidocaine that can be safely administered by the oral route, was given, as the sole drug, to four patients with active trigeminal neuralgia. After at least seven days on mexiletine they had no clear benefit. The four patients subsequently improved with carbamazepine or phenytoin. Our observations suggest that mexiletine alone is not of value in trigeminal neuralgia.
Adverse Reactions to Iopamidol and Iohexol Myelography with Special Attention to Headache: Role of Myelographic Technique
Authors: Sobel David F. , Rowe Rekarda , Zyroff Jack , Koziol James A. , Frost Francine , Krupsaw Jean 
Published: June 2005

SYNOPSISIn order to identify those myelographic risk factors associated with a higher incidence of adverse effects, myelographic technique, patient variables and post‐myelographic symptoms were prospectively recorded in a group of 152 patients studied with iopamidol and in a second group of 28 patients studied with iohexol.None of the technical factors studied were identified to have a statistically significant relationship with the incidence of adverse reactions. Older patients fared better than younger patients in both groups. Overall, there was a lower incidence of side effects in the iopomidol group (29%) than in the iohexol group (50%). Headache, nausea, and vomiting were the most frequent reactions seen.
Migraine ‐ A Risk Factor for Dissection of Cervical Arteries
Authors: D'Anglejan‐Chatillon J. , Ribeiro V. , Mas J.L. , Youl B.D. , Bousser M.G. 
Published: June 2005

SYNOPSISA case control study technique was employed to test for an association between non‐traumatic cervical artery dissection and several possible risk factors. A significant positive association was shown with migraine, independent of type and treatment regimen. No such relationship was found with smoking history, hypertension or past oral contraceptive use. There was, however a significant and independent association with current oral contraceptive use.
Prevalence and Clinical Features of Migraine: A Community Survey in Bangkok, Thailand
Authors: Phanthumchinda Kammant , Sithi‐Amorn Chitr 
Published: June 2005

SYNOPSISThe authors probed the extent and clinical features of migraine through a community survey in the Bangkokslum. A total population of 540 individuals of both sexes were randomly selected from available subjects. They were interviewed using questionnaires. The response rate was 100%. The prevalence of migraine in the previous year in 135 men and 405 women was 10.4% and 35.3% respectively. The overall prevalence of migraine in this community was 29.1%. In both sexes, the prevalence declined with increasing age and in women, the effect of age was significant (p<.005). The clinical features of migraine (age of onset, headache profile, neurological symptoms, severity and frequency of headache, familial history, precipitating factors and medications for headache) were analyzed. We concluded that migraine is not uncommon in a low socioeconomic group in Thailand, and that this type of headache is a burden to patients and may have some economic effect. Thus, strategy in prevention and control of migraine should be critically considered.
Epidural Blood Patch in the Treatment of Post Dural Puncture Headache: A Double Blind Study
Authors: Seebacher J. , Ribeiro V. , LeGuillou J. L. , Lacomblez L. , Henry M. , Thorman F. , Youl B. , Bensimon G. , Darbois Y. , Bousser M.G. 
Published: June 2005

SYNOPSISA randomised double blind controlled trial of ‘epidural blood‐patch’ as treatment for post‐dural puncture headache is presented. The method was successful in 11 out of 12 cases on its first application, the twelfth patient being relieved by a second procedure. None of six patients reported benefit from a ‘sham’ procedure. The rationale for the use of the technique is discussed.
European Multicenter Trial of Nimodipine in the Prophylaxis of Common Migraine (Migraine Without Aura)
Authors:   Migraine‐Nimodipine European Study Group (MINES)
Published: June 2005

SYNOPSISThis double blind, randomized study of the calcium antagonist Nimodipine 40 mg t.i.d. vs placebo in the prophylaxis of common migraine (migraine without aura) included 192 patients. Patients with 2–8 migraine days/4 weeks, age 18–60, who had no other types of recurring headaches except up to 6 interval headaches/4 weeks were included. The study was carried out at 11 European centers. After a 4 week run‐in period, patients were randomly allocated to Nimodipine or placebo for 12 weeks (parallel groups). There were 19 drop‐outs, 12 on Nimodipine and 7 on placebo, A gradual and marked improvement was seen both with Nimodipine and with placebo amounting to approximately 60% during the last 4 weeks. Statistical analysis on all included patients (intention to treat) revealed no difference between Nimodipine and placebo for migraine days (P = 0.69) or migraine index (p = 0.91). In patients “valid for analysis of efficacy” there were also no significant differences. Due to a very marked placebo effect and use of the parallel groups design, the present trial was not very powerful despite the large number of patients and a satisfactory compliance. We cannot rule out that Nimodipine might have up to 30% effect on a single main outcome parameter, but the uniform lack of response in all tested parameters makes this unlikely. Therefore Nimodipine probably has only a small or no effect in common migraine (migraine without aura).
European Multicenter Trial of Nimodipine in the Prophylaxis of Classic Migraine (Migraine With Aura)
Authors:   Migraine‐Nimodipine European Study Group (MINES)
Published: June 2005

SYNOPSISThis double‐blind, randomized study of the Nimodipine 40 mg t.i.d. vs placebo in the prophylaxis of classic migraine (migraine with aura) included 89 patients. Required migraine frequency was 2–8 migraine days/4 weeks and at least two of the attacks within the last 6 months had to be with aura. The study was carried out at 11 European centers. After a 4 week run‐in period, patients were randomly allocated to nimodipine or placebo for 12 weeks (parallel groups). There were 7 dropouts, 3 on Nimodipine, and 4 on placebo. A gradual and verymarked improvement was seen both with Nimodipine and placebo amounting to between 60 and 90 per cent during the last 4 weeks. Statistical analysis on all included patients (intention to treat) revealed no difference between Nimodipine and placebo for migraine days or migraine index. In patients “valid for analysis of efficacy” there were also no significant difference. Due to a very marked placebo effect and use of the parallel groups design, the present trial is relatively weak despite a fairly large sample size. It cannot rule out the possibility of an important effect of Nimodipine in classic migraine with a high degree of certainty.
Assessing the effectiveness of whole blood–derived platelets stored as a pool: a randomized block noninferiority trial
Authors: Heddle N.M. , Cook R.J. , Blajchman M.A. , Barty R.L. , Sigouin C.S. , Boye D.M. , Nelson E.J. , Kelton J.G. 
Published: June 2005

BACKGROUND: Prestorage pooling of whole blood–derived platelets (PLTs) would simplify bacterial detection. This study evaluated the in vivo effect of the prestorage pooling of PLTs stored for up to 5 days, by assessing the corrected count increment (CCI) 18 to 24 hours after transfusion of the product.STUDY DESIGN AND METHODS: A randomized block noninferiority design was used. Eligible patients had chemotherapy‐induced thrombocytopenia and were considered likely to need at least six PLT transfusions. For every block of two transfusion events, one consisted of PLTs stored individually and then pooled before transfusion, and the other was a product pooled before storage. The primary outcome was categorized as a successful (>4.5) or unsuccessful (≤4.5) 18‐ to 24‐hour posttransfusion CCI analyzed with a matched pair score test. A mixed‐effect linear model estimated the mean difference in CCI between the two types of storage.RESULTS: Twenty‐three eligible patients received a total of 189 PLT transfusions. The median number of PLT transfusions was 7 (range, 0‐27). Eighty‐five complete transfusion pairs were used in the primary analysis. The proportions of transfusions leading to a CCI of greater than 4.5 was identical for both routine and PLTs pooled before storage (45/85 = 52.9%; relative risk, 1.00; lower limit of the one‐sided 95% confidence interval [CI], 0.83). The estimate of the mean difference in CCI between pooled and routine storage (pooled − routine) was −0.45 (95% CI, −2.23 to 1.33; p = 0.63).CONCLUSION: These results provide evidence that storage of PLTs as a pool for up to 5 days results in posttransfusion CCIs that are not inferior to PLTs stored individually.
Delayed platelet engraftment in group O patients after autologous progenitor cell transplantation
Authors: Hoffmann Sandra , Zhou Lan , Gu Yuan , Davenport Robertson , Cooling Laura 
Published: June 2005

BACKGROUND: Fucosylated glycans, including H‐antigen, play critical roles in hematopoietic progenitor cell homing, adhesion, growth, and differentiation. H‐active antigens are strongly expressed on CD34+ progenitor cells and committed megakaryocytic progenitors and may mediate adhesion to marrow stromal fibroblasts. We examined the possible influence of donor ABO type on platelet (PLT) engraftment after autologous peripheral blood progenitor cell transplant (PBPCT).STUDY DESIGN AND METHODS: A retrospective analysis of all patients who underwent a single autologous PBPCT between 1996 and 2000 were reviewed. Neutrophil and PLT engraftment were compared by patient ABO type and CD34+ cell dose by t test, chi‐square test, analysis of variance, Kaplan‐Meier probability, and log‐rank test.RESULTS: Engraftment data was available in 195 patients. PLT engraftment was delayed in all patients, regardless of ABO type, at CD34+ PBPC doses of 2 × 106 to 3 × 106 per kg (p < 0.001). When examined by ABO type, late PLT engraftment (PLT count > 50 × 109/L) was significantly delayed in group O patients relative to all non‐group O patients (32.4 days vs. 19.6 days, p < 0.001). Approximately 50 percent of group O patients required more than 40 days to achieve late PLT recovery (p < 0.005).CONCLUSIONS: A group O phenotype may be associated with delayed PLT engraftment at lower CD34 doses.
Parvovirus B19 transmission by a high‐purity factor VIII concentrate
Authors: Wu Chuan‐ging , Mason Bobby , Jong Julia , Erdman Dean , McKernan Laurel , Oakley Meredith , Soucie Mike , Evatt Bruce , Yu Mei‐ying W. 
Published: June 2005

BACKGROUND: Parvovirus B19 (B19) is known to cause a variety of human diseases in susceptible individuals by close contact via the respiratory route or by transfusion of contaminated blood or blood products. In this study, whether a case of B19 transmission was causally related to the infusion of implicated lots of a solvent/detergent (S/D)‐treated, immunoaffinity‐purified factor VIII concentrate (antihemophilic factor [human][AHF]) was investigated.STUDY DESIGN AND METHODS: Anti‐B19 (both immunoglobulin M [IgM] and immunoglobulin G [IgG]) and B19 DNA (by a nucleic acid testing [NAT] procedure) were assayed in two implicated product lots, a plasma pool, and a recipient's serum sample. Analysis of the partial B19 sequences obtained from sequencing clones or direct sequencing of the samples was performed.RESULTS: Only one of the two implicated lots was B19 DNA–positive. It contained 1.3 × 103 genome equivalents (geq or international units [IU]) per mL. The negative lot was derived from plasma screened for B19 DNA by NAT in a minipool format to exclude high‐titer donations, whereas the positive lot was mostly from unscreened plasma. This high‐purity AHF product had no detectable anti‐B19 IgG. A 4‐week postinfusion serum sample from a recipient, who received both lots and became ill, was positive for the presence of B19 antibodies (both IgM and IgG) as well as B19 DNA. The B19 sequences from the positive lot, its plasma pool, and the recipient's serum sample were closely related.CONCLUSION: These findings and the recipient's clinical history support a causal relationship between the implicated AHF product and B19 infection in this recipient. The seronegative patient became infected after receiving 2 × 104 IU (or geq) of B19 DNA, which was present in this S/D‐treated, high‐purity AHF product.